GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-12-16
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 559
- Registration Number
- NCT00266227
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
Phase 3
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1237
- Registration Number
- NCT00262067
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2005-11-23
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1145
- Registration Number
- NCT00257608
- Locations
- 🇺🇸
Siouxland Hem-Onc Assoc LLP, Sioux City, Iowa, United States
🇺🇸Montana Cancer Specialists, Missoula, Montana, United States
🇺🇸Coastal Bend Cancer Center, Corpus Christi, Texas, United States
A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 8023
- Registration Number
- NCT00252135
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Phase 3
Completed
- Conditions
- Choroidal NeovascularizationAge-related Macular Degeneration
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 5000
- Registration Number
- NCT00251459
A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-10-24
- Last Posted Date
- 2011-10-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT00243412
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Phase 2
Completed
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 262
- Registration Number
- NCT00137969
- Locations
- 🇺🇸
Univ of Calif., Los Angeles; Rheumatology, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 636
- Registration Number
- NCT00130728
- Locations
- 🇺🇸
Kaiser Permanente - Vallejo, Vallejo, California, United States
🇺🇸Anne Arundel Health System Research Instit-Annapolis Oncology Ctr, Annapolis, Maryland, United States
🇺🇸University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States
A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
Phase 4
Terminated
- Conditions
- Colorectal Cancer
- First Posted Date
- 2005-06-21
- Last Posted Date
- 2006-05-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT00114946
A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Phase 3
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-04-27
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 686
- Registration Number
- NCT00109317
© Copyright 2025. All Rights Reserved by MedPath